We cannot exclude the possibility that her cancer, including the HER2+ components, may have responded to the chemotherapy in KN-522 alone even without HER2 targeting agents, but we believe that this treatment paradigm represents a superior treatment option for this patient as it is specifically tailored to the complex biology of her cancer. The gene discussed is ERBB2; the disease is cancer.